Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ADK | P55263 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17038781 | 0.88 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDKDM4EPOLBMEN1 | |
| SCHEMBL29564805 | 0.88 | SMN1; SMN2 (0.74) | SMN1; SMN2HPGDKDM4EPOLBMEN1 | |
| SCHEMBL14760340 | 0.86 | LMNA (0.54) | SMN1; SMN2HPGDKDM4EPOLBMEN1 | |
| SCHEMBL22581855 | 0.84 | KDM4E (0.69) | SMN1; SMN2HPGDKDM4EPOLBMEN1 | |
| SCHEMBL5916500 | 0.83 | GRM5 (0.57) | ADK | |
| SCHEMBL17035903 | 0.81 | SMN1; SMN2 (0.63) | SMN1; SMN2HPGDKDM4EPOLBMEN1 | |
| SCHEMBL5916462 | 0.79 | ADK (0.58) | SMN1; SMN2HPGDADKPANK3 | |
| SCHEMBL31605471 | 0.79 | HPGD (0.61) | SMN1; SMN2HPGDADKKDM4EPOLB | |
| SCHEMBL31381853 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2HPGDKDM4EPOLBMEN1 | |
| SCHEMBL31410511 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2HPGDKDM4EPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558578-B1 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-03-13 | — | — | EP | claimed |
| US-7153857-B2 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | US | disclosed |
| US-20040220185-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | disclosed |
| EP-1417201-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003014111-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229313-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | SMN1; SMN2 3356/4885HPGD 119/4885ADK 4207/4885 |
| US-20040220185-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | SMN1; SMN2 3001/4885HPGD 131/4885ADK 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.